RT Journal Article
T1 Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism.
A1 Ruiz-Artacho, Pedro
A1 Lecumberri, Ramón
A1 Trujillo-Santos, Javier
A1 Font, Carme
A1 López-Núñez, Juan J
A1 Peris, María Luisa
A1 Díaz Pedroche, Carmen
A1 Lobo, José Luis
A1 López Jiménez, Luciano
A1 López Reyes, Raquel
A1 Jara Palomares, Luis
A1 Pedrajas, José María
A1 Mahé, Isabelle
A1 Monreal, Manuel
A1 The Riete Investigators, 
K1 adenocarcinoma lung cancer
K1 cancer associated thrombosis
K1 histology
K1 lung cancer
K1 venous thrombolism
AB Background: In patients with lung cancer and venous thromboembolism (VTE), the influence of cancer histology on outcome has not been consistently evaluated. Methods: We used the RIETE registry (Registro Informatizado Enfermedad TromboEmbólica) to compare the clinical characteristics and outcomes during anticoagulation in patients with lung cancer and VTE, according to the histology of lung cancer. Results: As of April 2022, there were 482 patients with lung cancer and VTE: adenocarcinoma 293 (61%), squamous 98 (20%), small-cell 44 (9.1%), other 47 (9.8%). The index VTE was diagnosed later in patients with squamous cancer than in those with adenocarcinoma (median, 5 vs. 2 months). In 50% of patients with adenocarcinoma, the VTE appeared within the first 90 days since cancer diagnosis. During anticoagulation (median 106 days, IQR: 45-214), 14 patients developed VTE recurrences, 15 suffered major bleeding, and 218 died: fatal pulmonary embolism 10, fatal bleeding 2. The rate of VTE recurrences was higher than the rate of major bleeding in patients with adenocarcinoma (11 vs. 6 events), and lower in those with other cancer types (3 vs. 9 events). On multivariable analysis, patients with adenocarcinoma had a non-significantly higher risk for VTE recurrences (hazard ratio [HR]: 3.79; 95%CI: 0.76-18.8), a lower risk of major bleeding (HR: 0.29; 95%CI: 0.09-0.95), and a similar risk of mortality (HR: 1.02; 95%CI: 0.76-1.36) than patients with other types of lung cancer. Conclusions: In patients with lung adenocarcinoma, the rate of VTE recurrences outweighed the rate of major bleeding. In patients with other lung cancers, it was the opposite.
SN 2072-6694
YR 2022
FD 2022-08-26
LK http://hdl.handle.net/10668/20914
UL http://hdl.handle.net/10668/20914
LA en
DS RISalud
RD Apr 7, 2025